Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives
AbstractMultidrug resistance (MDR) presents a serious challenge to the efficiency of cancer treatment, and may be associated with the overexpression of drug efflux pumps. P-glycoprotein (P-gp) is a drug efflux pump often found overexpressed in cases of acquired MDR. Nevertheless, there are no P-gp inhibitors being used in the current clinical practice, due to toxicity problems, drug interactions, or pharmacokinetic issues. Therefore, it is important to identify novel inhibitors of P-gp activity or expression. Curcumin is a secondary metabolite isolated from the turmeric of Curcuma longa L. which has been associated with several biological activities, particularly P-gp modulatory activity (by inhibiting both P-gp function and expression). However, curcumin shows extensive metabolism and instability, which has justified the recent and intensive search for analogs of curcumin that maintain the P-gp modulatory activity but have enhanced stability. This review summarizes and compares the effects of curcumin and several curcumin analogs on P-glycoprotein function and expression, emphasizing the potential of these molecules for the possible development of safe and effective inhibitors of P-gp to overcome MDR in human cancer. View Full-Text
Share & Cite This Article
Lopes-Rodrigues, V.; Sousa, E.; Vasconcelos, M.H. Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives. Pharmaceuticals 2016, 9, 71.
Lopes-Rodrigues V, Sousa E, Vasconcelos MH. Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives. Pharmaceuticals. 2016; 9(4):71.Chicago/Turabian Style
Lopes-Rodrigues, Vanessa; Sousa, Emília; Vasconcelos, M. H. 2016. "Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives." Pharmaceuticals 9, no. 4: 71.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.